Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 801-821
Open Access | Times Cited: 160

Showing 26-50 of 160 citing articles:

Assessing the contribution of myelofibrosis to a leukoerythroblastic blood picture
Stephen E. Langabeer
Hematology Transfusion and Cell Therapy (2025) Vol. 47, Iss. 1, pp. 103735-103735
Open Access
Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects
Jun Dai, Cheng Yang, Yannan Zhou, et al.
Cancer Chemotherapy and Pharmacology (2025) Vol. 95, Iss. 1
Closed Access
Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis
Rithin Nedumannil, Tal Karmi, Piers Blombery, et al.
British Journal of Haematology (2025)
Closed Access
Ruxolitinib as a Novel Therapeutic Agent Targeting Mitochondrial Function and Chemo-Resistance in Nasopharyngeal Carcinoma
Lin Liu, Yongbo Zhu, Yunlong Zhang
Biochemical and Biophysical Research Communications (2025) Vol. 753, pp. 151486-151486
Closed Access
CALR—mutant myeloproliferative neoplasms: insights from next-generation sequencing
Aleksandra Mroczkowska-Bękarciak, Agnieszka Szeremet, Olga Chyrko, et al.
Journal of Applied Genetics (2025)
Open Access
Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Ivan Krečak, Marko Lucijanić, Rajko Kušec
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1524-1524
Open Access
Targeting CD38 effectively prevents myelofibrosis in myeloproliferative neoplasms
Yiru Yan, Jinqin Liu, Sophia Zhao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals
Francesca Palandri, Alessandro Inzoli, Antonella Barone, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Nature Medicine (2025)
Open Access
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Giuseppe Gaetano Loscocco, Paola Guglielmelli
American Journal of Hematology (2025)
Open Access
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2025)
Closed Access
Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis
Tom Liu, Mirko Fillbrunn, Shiyuan Zhang, et al.
Annals of Hematology (2025)
Open Access
Neutrophils in BCR::ABL1 negative MPN: Contributors or bystanders of fibrosis?
Gaël Vermeersch, Mieke Gouwy, Paul Proost, et al.
Blood Reviews (2025), pp. 101285-101285
Closed Access
The Molecular Mechanisms of Bergapten Against Abdominal Aortic Aneurysm: Evidence From Network Pharmacology, Molecular Docking/Dynamics, and Experimental Validation
Fujia Xu, Sihan Luo, Zhenhua Huang, et al.
Journal of Cellular Biochemistry (2025) Vol. 126, Iss. 4
Closed Access
Clearance of Driver Mutations in Myelofibrosis

New England Journal of Medicine (2025) Vol. 392, Iss. 13, pp. 1348-1349
Closed Access
Lysyl oxidase like-2 in fibrosis and cardiovascular disease
Alan Poe, Marta Martinez Yus, Huilei Wang, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 3, pp. C694-C707
Closed Access | Times Cited: 11
Cancer-associated splanchnic vein thrombosis: Clinical implications and management considerations
Omri Cohen, Lucia Caiano, Sarina Levy‐Mendelovich
Thrombosis Research (2024) Vol. 234, pp. 75-85
Closed Access | Times Cited: 3
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature
Hannah Goulart, Lucia Masarová, Ruben A. Mesa, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 48-60
Closed Access | Times Cited: 3
Targeting exhausted cytotoxic T cells through CTLA‐4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts
Lara Tavernari, Sebastiano Rontauroli, Ruggiero Norfo, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 10, pp. 1939-1950
Open Access | Times Cited: 3
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 13, pp. 1449-1461
Closed Access | Times Cited: 7
Recent advances in therapies for primary myelofibrosis
William Vainchenker, Nasrine Yahmi, Violaine Havelange, et al.
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 7
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 978-981
Closed Access | Times Cited: 2
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
Abdulraheem Yacoub, Nicole Twardowski, Alec Britt, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 8, pp. 506-511
Open Access | Times Cited: 2
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Cytogenetics and genomics in CML and other myeloproliferative neoplasms
Hans Kreipe, Brigitte Schlegelberger
Best Practice & Research Clinical Haematology (2024) Vol. 37, Iss. 2, pp. 101552-101552
Open Access | Times Cited: 2

Scroll to top